NTHI (NeOnc Technologies Holdings) 3-Year EBITDA Growth Rate: -172.40% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NTHI NeOnc Technologies Holdings Inc NTHI
11 GF Score
Price $4.68
! 1 Warning Sign
View Full Analysis

What is NeOnc Technologies Holdings 3-Year EBITDA Growth Rate?

NeOnc Technologies Holdings NTHI +2.63% 11 3-Year EBITDA Growth Rate is -172.40% as of Jun. 2026. GuruFocus rates NTHI with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,129 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 99.56% on this metric.

NeOnc Technologies Holdings's EBITDA per Share for the three months ended in Jun. 2026 was $-0.57.

During the past 3 years, the average EBITDA Per Share Growth Rate was -172.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of NeOnc Technologies Holdings was -40.70% per year. The lowest was -172.40% per year. And the median was -106.55% per year.

NeOnc Technologies Holdings  (NAS:NTHI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

NeOnc Technologies Holdings 3-Year EBITDA Growth Rate Related Terms

NTHI vs BMEA, PTHS, ALDX: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, NeOnc Technologies Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeOnc Technologies Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where NeOnc Technologies Holdings's 3-Year EBITDA Growth Rate falls into.


NTHI
11GF Score
NeOnc Technologies Holdings Inc NTHI
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeOnc Technologies Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of -172.40% mean?
NeOnc Technologies Holdings (NTHI) has a 3-Year EBITDA Growth Rate of -172.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NeOnc Technologies Holdings and its competitors. According to the industry distribution chart, NeOnc Technologies Holdings ranks #1124 out of 1129 companies in the Biotechnology industry, placing it in the top 99.6%.
Is NeOnc Technologies Holdings' 3-Year EBITDA Growth Rate too high?
NeOnc Technologies Holdings' current 3-Year EBITDA Growth Rate is -172.40%. Based on the distribution chart, NeOnc Technologies Holdings ranks #1124 out of 1129 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' 3-Year EBITDA Growth Rate compare to BMEA and PTHS?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #1124 out of 1129 companies for 3-Year EBITDA Growth Rate. This places NeOnc Technologies Holdings in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NeOnc Technologies Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeOnc Technologies Holdings's current 3-Year EBITDA Growth Rate is -172.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current 3-Year EBITDA Growth Rate of -172.40%. The current 3-Year EBITDA Growth Rate is -172.40%. NeOnc Technologies Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current 3-Year EBITDA Growth Rate is -172.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NeOnc Technologies Holdings Business Description

Address 23975 Park Sorrento, Suite 205, Calabasas, CA, USA, 91302
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
11GF Score

Get the complete analysis for NTHI

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.68
Price